title: A safe, effective, and facility compatible cleaning in place procedure for affinity resin in large-scale monoclonal antibody purification.
abstract: Cleaning-in-place (CIP) for column chromatography plays an important role in therapeutic protein production. A robust and efficient CIP procedure ensures product quality, improves column life time and reduces the cost of the purification processes, particularly for those using expensive affinity resins, such as MabSelect protein A resin. Cleaning efficiency, resin compatibility, and facility compatibility are the three major aspects to consider in CIP process design. Cleaning MabSelect resin with 50mM sodium hydroxide (NaOH) along with 1M sodium chloride is one of the most popular cleaning procedures used in biopharmaceutical industries. However, high concentration sodium chloride is a leading cause of corrosion in the stainless steel containers used in large scale manufacture. Corroded containers may potentially introduce metal contaminants into purified drug products. Therefore, it is challenging to apply this cleaning procedure into commercial manufacturing due to facility compatibility and drug safety concerns. This paper reports a safe, effective and environmental and facility-friendly cleaning procedure that is suitable for large scale affinity chromatography. An alternative salt (sodium sulfate) is used to prevent the stainless steel corrosion caused by sodium chloride. Sodium hydroxide and salt concentrations were optimized using a high throughput screening approach to achieve the best combination of facility compatibility, cleaning efficiency and resin stability. Additionally, benzyl alcohol is applied to achieve more effective microbial control. Based on the findings, the recommended optimum cleaning strategy is cleaning MabSelect resin with 25 mM NaOH, 0.25 M Na2SO4 and 1% benzyl alcohol solution every cycle, followed by a more stringent cleaning using 50 mM NaOH with 0.25 M Na2SO4 and 1% benzyl alcohol at the end of each manufacturing campaign. A resin life cycle study using the MabSelect affinity resin demonstrates that the new cleaning strategy prolongs resin life time and consistently delivers high purity drug products.
authors: Process Science, Bristol-Myers Squibb Company, Bloomsbury, NJ, USA. lu.wang@bms.com
authors: Lu
authors: L
authors: Wang
authors: Jill
authors: J
authors: Dembecki
authors: Neil E
authors: NE
authors: Jaffe
authors: Brian W
authors: BW
authors: O'Mara
authors: Hui
authors: H
authors: Cai
authors: Colleen N
authors: CN
authors: Sparks
authors: Jian
authors: J
authors: Zhang
authors: Sarah G
authors: SG
authors: Laino
authors: Reb J
authors: RJ
authors: Russell
authors: Michelle
authors: M
authors: Wang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification*; D016466:CHO Cells; D002846:Chromatography, Affinity / Q000295:instrumentation* / Q000379:methods*; D006224:Cricetinae; D003412:Cricetulus; D046209:Electrophoresis, Microchip; D017743:Equipment Reuse; D057166:High-Throughput Screening Assays / Q000295:instrumentation / Q000379:methods; D011506:Proteins / Q000302:isolation & purification
chemical_list: D000911:Antibodies, Monoclonal; D011506:Proteins
keywords: Cleaning in place (CIP); Commercial scale purification; Facility compatible; High throughput screen; MabSelect; Resin life cycle